Phaseline

Companies › Xynomic Pharmaceuticals

Xynomic Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 19 registered trials: 8 Phase 2, 8 Phase 1, 3 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Abexinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Renal Cell Carcinoma; Lymphoma, Follicular; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma …Dec 2026
Pazopanib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04024696AbexinostatPhase 1Non Hodgkin LymphomaOncologyDec 2024
NCT02203760PazopanibPhase 2Leiomyosarcoma or CarcinosarcomaOncologyDec 2024
NCT02203760PazopanibPhase 2Leiomyosarcoma or CarcinosarcomaOncologyDec 2024
NCT03934567AbexinostatPhase 2Lymphoma, FollicularOncologyJan 2025
NCT06895733PazopanibPhase 1Solid Tumor, AdultOncologyDec 2025
NCT03592472AbexinostatPhase 3Renal Cell CarcinomaOncologyDec 2026
NCT03592472PazopanibPhase 3Renal Cell CarcinomaOncologyDec 2026
NCT05679921PazopanibPhase 2Soft Tissue SarcomaOncologyDec 2026
NCT06816771PazopanibPhase 2Rhabdomyosarcoma, Recurrent, RefractoryOncologyDec 2026
NCT05180695PazopanibPhase 1Advanced Soft-tissue SarcomaOncologyFeb 2027
NCT02331498PazopanibPhase 1Glioblastoma MultiformeOncologyFeb 2027
NCT05698524AbexinostatPhase 1Recurrent High Grade GliomaOncologyJul 2027
NCT03936153AbexinostatPhase 2Diffuse Large B-cell Lymphoma (DLBCL)OncologyAug 2027
NCT05210413PazopanibPhase 1Refractory or Recurrent Solid TumorOncologyNov 2027
NCT03600441AbexinostatPhase 2Follicular LymphomaOncologyDec 2027
NCT01217931PazopanibPhase 2Kidney CancerOncologyJan 2028
NCT01224288PazopanibPhase 3Renal Cell CarcinomaOncologyApr 2029
NCT07444619PazopanibPhase 1Soft Tissue SarcomasOncologyDec 2031
NCT06239272PazopanibPhase 1Adipocytic NeoplasmOncologyJun 2034

Targets

HDAC (class I/II) (1) CSF1R (1) KIT (1) LCK (1) FGFR3 (1) FGFR1 (1)

Companies with the same targets

Daiichi Sankyo Tyra Biosciences Deciphera Pharmaceuticals Exelixis Blueprint Medicines AstraZeneca Johnson & Johnson (Janssen) Hutchmed Novartis Gossamer Bio USA

Companies built like this

Acrotech Biopharma LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.